The role of oxidative stress in the initiation and progression of myelodysplastic syndromes (MDS) as a consequence of iron overload remains unclear. In this study we have simultaneously quantified plasma low-molecular-weight aminothiols, malondialdehyde, nitrite, and nitrate and have studied their correlation with serum iron/ferritin levels, patient treatment (chelation therapy), and clinical outcomes. We found significantly elevated plasma levels of total, oxidized, and reduced forms of cysteine (P < 0.001), homocysteine (P < 0.001), and cysteinylglycine (P < 0.006) and significantly depressed levels of total and oxidized forms of glutathione (P < 0.03) and nitrite (P < 0.001) in MDS patients compared to healthy donors. Moreover, total (P < 0.032) and oxidized cysteinylglycine (P = 0.029) and nitrite (P = 0.021) differed significantly between the analyzed MDS subgroups with different clinical classifications. Malondialdehyde levels in plasma correlated moderately with both serum ferritin levels (r = 0.78, P = 0.001) and serum free iron levels (r = 0.60, P = 0.001) and were significantly higher in patients with iron overload. The other analyzed compounds lacked correlation with iron overload (represented by serum iron/ferritin levels). For the first time our results have revealed significant differences in the concentrations of plasma aminothiols in MDS patients, when compared to healthy donors. We found no correlation of these parameters with iron overload and suggest the role of oxidative stress in the development of MDS disease.

Clinical Department Institute of Hematology and Blood Transfusion U Nemocnice 1 128 00 Prague 2 Czech Republic

Department of Biochemistry Institute of Hematology and Blood Transfusion U Nemocnice 1 128 00 Prague 2 Czech Republic

Zobrazit více v PubMed

Farquhar MJ, Bowen DT. Oxidative stress and the myelodysplastic syndromes. International Journal of Hematology. 2003;77(4):342–350. PubMed

Gattermann N, Rachmilewitz EA. Iron overload in MDS-pathophysiology, diagnosis, and complications. Annals of Hematology. 2011;90(1):1–10. PubMed

Saigo K, Takenokuchi M, Hiramatsu Y, et al. Oxidative stress levels in myelodysplastic syndrome patients: their relationship to serum ferritin and haemoglobin values. Journal of International Medical Research. 2011;39(5):1941–1945. PubMed

Ghoti H, Amer J, Winder A, Rachmilewitz E, Fibach E. Oxidative stress in red blood cells, platelets and polymorphonuclear leukocytes from patients with myelodysplastic syndrome. European Journal of Haematology. 2007;79(6):463–467. PubMed

Cortelezzi A, Cattaneo C, Cristiani S, et al. Non-transferrin-bound iron in myelodysplastic syndromes: a marker of ineffective erythropoiesis? Hematology Journal. 2000;1(3):153–158. PubMed

Cortelezzi A, Fracchiolla NS, Bamonti-Catena F, et al. Hyperhomocysteinemia in myelodysplastic syndromes: specific association with autoimmunity and cardiovascular disease. Leukemia and Lymphoma. 2001;41(1-2):147–150. PubMed

Peddie CM, Wolf CR, Mclellan LI, Collins AR, Bowen DT. Oxidative DNA damage in CD34+ myelodysplastic cells is associated with intracellular redox changes and elevated plasma tumour necrosis factor-α concentration. British Journal of Haematology. 1997;99(3):625–631. PubMed

Choi JW. No significant correlation exists between nitric oxide production and apoptosis in myelodysplastic syndromes. Acta Haematologica. 2003;109(1):50–52. PubMed

Giustarini D, Dalle-Donne I, Tsikas D, Rossi R. Oxidative stress and human diseases: origin, link, measurement, mechanisms, and biomarkers. Critical Reviews in Clinical Laboratory Sciences. 2009;46(5-6):241–281. PubMed

Raijmakers MTM, Steegers EAP, Peters WHM. Glutathione S-transferases and thiol concentrations in embryonic and early fetal tissues. Human Reproduction. 2001;16(11):2445–2450. PubMed

Garcia AJ, Apitz-Castro R. Plasma total homocysteine quantification: an improvement of the classical high-performance liquid chromatographic method with fluorescence detection of the thiol-SBD derivatives. Journal of Chromatography B. 2002;779(2):359–363. PubMed

Li H, Meininger CJ, Wu G. Rapid determination of nitrite by reversed-phase high-performance liquid chromatography with fluorescence detection. Journal of Chromatography B. 2000;746(2):199–207. PubMed

Woitzik J, Abromeit N, Schaefer F. Measurement of nitric oxide metabolites in brain microdialysates by a sensitive fluorometric high-performance liquid chromatography assay. Analytical Biochemistry. 2001;289(1):10–17. PubMed

Davies CA, Perrett D, Zhang Z, Nielsen BR, Blake DR, Winyard PG. Simultaneous analysis of nitrite, nitrate and the nicotinamide nucleotides by capillary electrophoresis: application to biochemical studies and human extracellular fluids. Electrophoresis. 1999;20(10):2111–2117. PubMed

Suttnar J, Mášová L, Dyr JE. Influence of citrate and EDTA anticoagulants on plasma malondialdehyde concentrations estimated by high-performance liquid chromatography. Journal of Chromatography B. 2001;751(1):193–197. PubMed

Štikarová J, Suttnar J, Pimková K, Chrastinová-Má Ová L, Ermák J, Dyr JE. Enhanced levels of asymmetric dimethylarginine in a serum of middle age patients with myelodysplastic syndrome. Journal of Hematology and Oncology. 2013;6(1, article 58) PubMed PMC

Moshage H, Kok B, Huizenga JR, Jansen PLM. Nitrite and nitrate determinations in plasma: a critical evaluation. Clinical Chemistry. 1995;41(6):892–896. PubMed

Kleinbongard P, Dejam A, Lauer T, et al. Plasma nitrite reflects constitutive nitric oxide synthase activity in mammals. Free Radical Biology and Medicine. 2003;35(7):790–796. PubMed

Lauer T, Preik M, Rassaf T, et al. Plasma nitrite rather than nitrate reflects regional endothelial nitric oxide synthase activity but lacks intrinsic vasodilator action. Proceedings of the National Academy of Sciences of the United States of America. 2001;98(22):12814–12819. PubMed PMC

Alusik S, Jedlickova V, Paluch Z, Zecova S. Plasma levels of nitrite/nitrate and inflammation markers in elderly individuals. Bratislavské lekárske listy. 2008;109(7):289–292. PubMed

Mikiwa K, Tadashi I, Kayoko K, et al. Plasma nitrate/nitrite concentration in healthy population and patients with diabetes mellitus: relationships with gender, aging and diabetic complications. Bulletin of the Osaka Medical College. 2002;48:1–6.

Bates CJ, Mansoor MA, Gregory J, Pentieva K, Prentice A. Correlates of plasma homocysteine, cysteine and cysteinyl-glycine in respondents in the British National Diet and Nutrition Survey of young people aged 4-18 years, and a comparison with the survey of people aged 65 years and over. British Journal of Nutrition. 2002;87(1):71–79. PubMed

Modun D, Krnic M, Vukovic J, et al. Plasma nitrite concentration decreases after hyperoxia-induced oxidative stress in healthy humans. Clinical Physiology and Functional Imaging. 2012;32(5):404–408. PubMed

Vermeulen Windsant IC, de Wit NC, Sertorio JT, et al. Blood transfusions increase circulating plasma free hemoglobin levels and plasma nitric oxide consumption: a prospective observational pilot study. Critical Care. 2012;16(3, article R95) PubMed PMC

Dreißigacker U, Suchy M-T, Maassen N, Tsikas D. Human plasma concentrations of malondialdehyde (MDA) and the F2-isoprostane 15(S)-8-iso-PGF2α may be markedly compromised by hemolysis: evidence by GC-MS/MS and potential analytical and biological ramifications. Clinical Biochemistry. 2010;43(1-2):159–167. PubMed

Mayer B, Andrew P. Nitric oxide synthases: catalytic function and progress towards selective inhibition. Naunyn-Schmiedeberg’s Archives of Pharmacology. 1998;358(1):127–133. PubMed

de Chiara B, Sedda V, Parolini M, et al. Plasma total cysteine and cardiovascular risk burden: action and interaction. Scientific World Journal. 2012;2012303654 PubMed PMC

Jacob N, Bruckert E, Giral P, Foglietti MJ, Turpin G. Cysteine is a cardiovascular risk factor in hyperlipidemic patients. Atherosclerosis. 1999;146(1):53–59. PubMed

Müller T, Muhlack S. Cysteinyl-glycine reduction as marker for levodopa-induced oxidative stress in Parkinson’s disease patients. Movement Disorders. 2011;26(3):543–546. PubMed

Passi S, Grandinetti M, Maggio F, Stancato A, De Luca C. Epidermal oxidative stress in vitiligo. Pigment Cell Research. 1998;11(2):81–85. PubMed

De Chiara B, Mafrici A, Campolo J, et al. Low plasma glutathione levels after reperfused acute myocardial infarction are associated with late cardiac events. Coronary Artery Disease. 2007;18(2):77–82. PubMed

Shimizu H, Kiyohara Y, Kato I, et al. Relationship between plasma glutathione levels and cardiovascular disease in a defined population: the Hisayama study. Stroke. 2004;35(9):2072–2077. PubMed

Hanigan MH, Frierson HF, Jr., Swanson PE, De Young BR. Altered expression of gamma-glutamyl transpeptidase in human tumors. Human Pathology. 1999;30(3):300–305. PubMed

Raza A, Galili N, Smith S, et al. Phase 1 multicenter dose-escalation study of ezatiostat hydrochloride (TLK199 tablets), a novel glutathione analog prodrug, in patients with myelodysplastic syndrome. Blood. 2009;113(26):6533–6540. PubMed

Dickinson DA, Forman HJ. Glutathione in defense and signaling: lessons from a small thiol. Annals of the New York Academy of Sciences. 2002;973:488–504. PubMed

Tager M, Ittenson A, Franke A, Frey A, Gassen HG, Ansorge S. γ-glutamyl transpepsidase-cellular expression in populations of normal human mononuclear cells and patients suffering from leukemias. Annals of Hematology. 1995;70(5):237–242. PubMed

Proctor MJ, Talwar D, Balmar SM, et al. The relationship between the presence and site of cancer, an inflammation-based prognostic score and biochemical parameters. Initial results of the Glasgow Inflammation Outcome Study. British Journal of Cancer. 2010;103(6):870–876. PubMed PMC

Diergaarde B, Brand R, Lamb J, et al. Pooling-based genome-wide association study implicates gamma- glutamyltransferase 1 (GGT1) gene in pancreatic carcinogenesis. Pancreatology. 2010;10(2-3):194–200. PubMed PMC

de Donatis GM, Moschini R, Cappiello M, del Corso A, Mura U. Cysteinyl-glycine in the control of glutathione homeostasis in bovine lenses. Molecular Vision. 2010;16:1025–1033. PubMed PMC

Vasikova A, Belickova M, Budinska E, Cermak J. A distinct expression of various gene subsets in CD34+ cells from patients with early and advanced myelodysplastic syndrome. Leukemia Research. 2010;34(12):1566–1572. PubMed

Valent P, Krieger O, Stauder R, et al. Iron overload in myelodysplastic syndromes (MDS): diagnosis, management, and response criteria: A proposal of the Austrian MDS platform. European Journal of Clinical Investigation. 2008;38(3):143–149. PubMed PMC

Toxic iron species in lower-risk myelodysplastic syndrome patients: course of disease and effects on outcome

Impact of treatment with iron chelation therapy in patients with lower-risk myelodysplastic syndromes participating in the European MDS registry